img

Global Inactivated Influenza Vaccine Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Inactivated Influenza Vaccine Market Research Report 2024

According to Mr Accuracy reports new survey, global Inactivated Influenza Vaccine market is projected to reach US$ 10610 million in 2029, increasing from US$ 6990 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Inactivated Influenza Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


CSL Limited
GSK
Sanofi Pasteur
Viatris
Hualan Biological
AstraZeneca
Sinovac Biotech
Aleph Biomedical
Abbott Laboratories
Novartis International
Changchun Institute of Biological
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

Segment by Application


Children
Adolescence
Adults
Elderly

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Inactivated Influenza Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Inactivated Influenza Vaccine Market Overview
1.1 Product Overview and Scope of Inactivated Influenza Vaccine
1.2 Inactivated Influenza Vaccine Segment by Type
1.2.1 Global Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Inactivated Influenza Vaccine Segment by Application
1.3.1 Global Inactivated Influenza Vaccine Market Value by Application: (2024-2034)
1.3.2 Children
1.3.3 Adolescence
1.3.4 Adults
1.3.5 Elderly
1.4 Global Inactivated Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Inactivated Influenza Vaccine Revenue 2018-2029
1.4.2 Global Inactivated Influenza Vaccine Sales 2018-2029
1.4.3 Global Inactivated Influenza Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Inactivated Influenza Vaccine Market Competition by Manufacturers
2.1 Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2018-2024)
2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Inactivated Influenza Vaccine Average Price by Manufacturers (2018-2024)
2.4 Global Inactivated Influenza Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Inactivated Influenza Vaccine, Product Type & Application
2.7 Inactivated Influenza Vaccine Market Competitive Situation and Trends
2.7.1 Inactivated Influenza Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Inactivated Influenza Vaccine Players Market Share by Revenue
2.7.3 Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Inactivated Influenza Vaccine Retrospective Market Scenario by Region
3.1 Global Inactivated Influenza Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Inactivated Influenza Vaccine Global Inactivated Influenza Vaccine Sales by Region: 2018-2029
3.2.1 Global Inactivated Influenza Vaccine Sales by Region: 2018-2024
3.2.2 Global Inactivated Influenza Vaccine Sales by Region: 2024-2029
3.3 Global Inactivated Influenza Vaccine Global Inactivated Influenza Vaccine Revenue by Region: 2018-2029
3.3.1 Global Inactivated Influenza Vaccine Revenue by Region: 2018-2024
3.3.2 Global Inactivated Influenza Vaccine Revenue by Region: 2024-2029
3.4 North America Inactivated Influenza Vaccine Market Facts & Figures by Country
3.4.1 North America Inactivated Influenza Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Inactivated Influenza Vaccine Sales by Country (2018-2029)
3.4.3 North America Inactivated Influenza Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Inactivated Influenza Vaccine Market Facts & Figures by Country
3.5.1 Europe Inactivated Influenza Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Inactivated Influenza Vaccine Sales by Country (2018-2029)
3.5.3 Europe Inactivated Influenza Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Inactivated Influenza Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Inactivated Influenza Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Inactivated Influenza Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Inactivated Influenza Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Inactivated Influenza Vaccine Market Facts & Figures by Country
3.7.1 Latin America Inactivated Influenza Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Inactivated Influenza Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Inactivated Influenza Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Inactivated Influenza Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Inactivated Influenza Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Inactivated Influenza Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Inactivated Influenza Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Inactivated Influenza Vaccine Sales by Type (2018-2029)
4.1.1 Global Inactivated Influenza Vaccine Sales by Type (2018-2024)
4.1.2 Global Inactivated Influenza Vaccine Sales by Type (2024-2029)
4.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Inactivated Influenza Vaccine Revenue by Type (2018-2029)
4.2.1 Global Inactivated Influenza Vaccine Revenue by Type (2018-2024)
4.2.2 Global Inactivated Influenza Vaccine Revenue by Type (2024-2029)
4.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Inactivated Influenza Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Inactivated Influenza Vaccine Sales by Application (2018-2029)
5.1.1 Global Inactivated Influenza Vaccine Sales by Application (2018-2024)
5.1.2 Global Inactivated Influenza Vaccine Sales by Application (2024-2029)
5.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Inactivated Influenza Vaccine Revenue by Application (2018-2029)
5.2.1 Global Inactivated Influenza Vaccine Revenue by Application (2018-2024)
5.2.2 Global Inactivated Influenza Vaccine Revenue by Application (2024-2029)
5.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Inactivated Influenza Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL Limited
6.1.1 CSL Limited Corporation Information
6.1.2 CSL Limited Description and Business Overview
6.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.1.4 CSL Limited Inactivated Influenza Vaccine Product Portfolio
6.1.5 CSL Limited Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.2.4 GSK Inactivated Influenza Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Corporation Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Viatris Inactivated Influenza Vaccine Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 Hualan Biological
6.5.1 Hualan Biological Corporation Information
6.5.2 Hualan Biological Description and Business Overview
6.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Hualan Biological Inactivated Influenza Vaccine Product Portfolio
6.5.5 Hualan Biological Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.6.4 AstraZeneca Inactivated Influenza Vaccine Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Sinovac Biotech
6.6.1 Sinovac Biotech Corporation Information
6.6.2 Sinovac Biotech Description and Business Overview
6.6.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Sinovac Biotech Inactivated Influenza Vaccine Product Portfolio
6.7.5 Sinovac Biotech Recent Developments/Updates
6.8 Aleph Biomedical
6.8.1 Aleph Biomedical Corporation Information
6.8.2 Aleph Biomedical Description and Business Overview
6.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Portfolio
6.8.5 Aleph Biomedical Recent Developments/Updates
6.9 Abbott Laboratories
6.9.1 Abbott Laboratories Corporation Information
6.9.2 Abbott Laboratories Description and Business Overview
6.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Portfolio
6.9.5 Abbott Laboratories Recent Developments/Updates
6.10 Novartis International
6.10.1 Novartis International Corporation Information
6.10.2 Novartis International Description and Business Overview
6.10.3 Novartis International Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Novartis International Inactivated Influenza Vaccine Product Portfolio
6.10.5 Novartis International Recent Developments/Updates
6.11 Changchun Institute of Biological
6.11.1 Changchun Institute of Biological Corporation Information
6.11.2 Changchun Institute of Biological Inactivated Influenza Vaccine Description and Business Overview
6.11.3 Changchun Institute of Biological Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Changchun Institute of Biological Inactivated Influenza Vaccine Product Portfolio
6.11.5 Changchun Institute of Biological Recent Developments/Updates
6.12 BCHT
6.12.1 BCHT Corporation Information
6.12.2 BCHT Inactivated Influenza Vaccine Description and Business Overview
6.12.3 BCHT Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.12.4 BCHT Inactivated Influenza Vaccine Product Portfolio
6.12.5 BCHT Recent Developments/Updates
6.13 Jiangsu GDK
6.13.1 Jiangsu GDK Corporation Information
6.13.2 Jiangsu GDK Inactivated Influenza Vaccine Description and Business Overview
6.13.3 Jiangsu GDK Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Jiangsu GDK Inactivated Influenza Vaccine Product Portfolio
6.13.5 Jiangsu GDK Recent Developments/Updates
6.14 KM Biologics
6.14.1 KM Biologics Corporation Information
6.14.2 KM Biologics Inactivated Influenza Vaccine Description and Business Overview
6.14.3 KM Biologics Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.14.4 KM Biologics Inactivated Influenza Vaccine Product Portfolio
6.14.5 KM Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Inactivated Influenza Vaccine Industry Chain Analysis
7.2 Inactivated Influenza Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Inactivated Influenza Vaccine Production Mode & Process
7.4 Inactivated Influenza Vaccine Sales and Marketing
7.4.1 Inactivated Influenza Vaccine Sales Channels
7.4.2 Inactivated Influenza Vaccine Distributors
7.5 Inactivated Influenza Vaccine Customers
8 Inactivated Influenza Vaccine Market Dynamics
8.1 Inactivated Influenza Vaccine Industry Trends
8.2 Inactivated Influenza Vaccine Market Drivers
8.3 Inactivated Influenza Vaccine Market Challenges
8.4 Inactivated Influenza Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Inactivated Influenza Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Inactivated Influenza Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Inactivated Influenza Vaccine Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Inactivated Influenza Vaccine Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Inactivated Influenza Vaccine Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Inactivated Influenza Vaccine Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Inactivated Influenza Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Inactivated Influenza Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Inactivated Influenza Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Inactivated Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Inactivated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 18. Global Inactivated Influenza Vaccine Sales Market Share by Region (2018-2024)
Table 19. Global Inactivated Influenza Vaccine Sales by Region (2024-2029) & (K Units)
Table 20. Global Inactivated Influenza Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Inactivated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2024)
Table 23. Global Inactivated Influenza Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 27. North America Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 28. North America Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 32. Europe Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 33. Europe Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Inactivated Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Inactivated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Inactivated Influenza Vaccine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Inactivated Influenza Vaccine Sales (K Units) by Type (2018-2024)
Table 51. Global Inactivated Influenza Vaccine Sales (K Units) by Type (2024-2029)
Table 52. Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2024)
Table 53. Global Inactivated Influenza Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Inactivated Influenza Vaccine Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Inactivated Influenza Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2024)
Table 57. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Inactivated Influenza Vaccine Price (US$/Unit) by Type (2018-2024)
Table 59. Global Inactivated Influenza Vaccine Price (US$/Unit) by Type (2024-2029)
Table 60. Global Inactivated Influenza Vaccine Sales (K Units) by Application (2018-2024)
Table 61. Global Inactivated Influenza Vaccine Sales (K Units) by Application (2024-2029)
Table 62. Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2024)
Table 63. Global Inactivated Influenza Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Inactivated Influenza Vaccine Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Inactivated Influenza Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2024)
Table 67. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Inactivated Influenza Vaccine Price (US$/Unit) by Application (2018-2024)
Table 69. Global Inactivated Influenza Vaccine Price (US$/Unit) by Application (2024-2029)
Table 70. CSL Limited Corporation Information
Table 71. CSL Limited Description and Business Overview
Table 72. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. CSL Limited Inactivated Influenza Vaccine Product
Table 74. CSL Limited Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. GSK Inactivated Influenza Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Sanofi Pasteur Corporation Information
Table 81. Sanofi Pasteur Description and Business Overview
Table 82. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Sanofi Pasteur Inactivated Influenza Vaccine Product
Table 84. Sanofi Pasteur Recent Developments/Updates
Table 85. Viatris Corporation Information
Table 86. Viatris Description and Business Overview
Table 87. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Viatris Inactivated Influenza Vaccine Product
Table 89. Viatris Recent Developments/Updates
Table 90. Hualan Biological Corporation Information
Table 91. Hualan Biological Description and Business Overview
Table 92. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Hualan Biological Inactivated Influenza Vaccine Product
Table 94. Hualan Biological Recent Developments/Updates
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. AstraZeneca Inactivated Influenza Vaccine Product
Table 99. AstraZeneca Recent Developments/Updates
Table 100. Sinovac Biotech Corporation Information
Table 101. Sinovac Biotech Description and Business Overview
Table 102. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Sinovac Biotech Inactivated Influenza Vaccine Product
Table 104. Sinovac Biotech Recent Developments/Updates
Table 105. Aleph Biomedical Corporation Information
Table 106. Aleph Biomedical Description and Business Overview
Table 107. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Aleph Biomedical Inactivated Influenza Vaccine Product
Table 109. Aleph Biomedical Recent Developments/Updates
Table 110. Abbott Laboratories Corporation Information
Table 111. Abbott Laboratories Description and Business Overview
Table 112. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Abbott Laboratories Inactivated Influenza Vaccine Product
Table 114. Abbott Laboratories Recent Developments/Updates
Table 115. Novartis International Corporation Information
Table 116. Novartis International Description and Business Overview
Table 117. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Novartis International Inactivated Influenza Vaccine Product
Table 119. Novartis International Recent Developments/Updates
Table 120. Changchun Institute of Biological Corporation Information
Table 121. Changchun Institute of Biological Description and Business Overview
Table 122. Changchun Institute of Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Changchun Institute of Biological Inactivated Influenza Vaccine Product
Table 124. Changchun Institute of Biological Recent Developments/Updates
Table 125. BCHT Corporation Information
Table 126. BCHT Description and Business Overview
Table 127. BCHT Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. BCHT Inactivated Influenza Vaccine Product
Table 129. BCHT Recent Developments/Updates
Table 130. Jiangsu GDK Corporation Information
Table 131. Jiangsu GDK Description and Business Overview
Table 132. Jiangsu GDK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Jiangsu GDK Inactivated Influenza Vaccine Product
Table 134. Jiangsu GDK Recent Developments/Updates
Table 135. KM Biologics Corporation Information
Table 136. KM Biologics Description and Business Overview
Table 137. KM Biologics Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. KM Biologics Inactivated Influenza Vaccine Product
Table 139. KM Biologics Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Inactivated Influenza Vaccine Distributors List
Table 143. Inactivated Influenza Vaccine Customers List
Table 144. Inactivated Influenza Vaccine Market Trends
Table 145. Inactivated Influenza Vaccine Market Drivers
Table 146. Inactivated Influenza Vaccine Market Challenges
Table 147. Inactivated Influenza Vaccine Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Inactivated Influenza Vaccine
Figure 2. Global Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Inactivated Influenza Vaccine Market Share by Type in 2022 & 2029
Figure 4. Trivalent Influenza Vaccine Product Picture
Figure 5. Quadrivalent Influenza Vaccine Product Picture
Figure 6. Global Inactivated Influenza Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Inactivated Influenza Vaccine Market Share by Application in 2022 & 2029
Figure 8. Children
Figure 9. Adolescence
Figure 10. Adults
Figure 11. Elderly
Figure 12. Global Inactivated Influenza Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Inactivated Influenza Vaccine Market Size (2018-2029) & (US$ Million)
Figure 14. Global Inactivated Influenza Vaccine Sales (2018-2029) & (K Units)
Figure 15. Global Inactivated Influenza Vaccine Average Price (US$/Unit) & (2018-2029)
Figure 16. Inactivated Influenza Vaccine Report Years Considered
Figure 17. Inactivated Influenza Vaccine Sales Share by Manufacturers in 2022
Figure 18. Global Inactivated Influenza Vaccine Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Inactivated Influenza Vaccine Players: Market Share by Revenue in 2022
Figure 20. Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Inactivated Influenza Vaccine Sales Market Share by Country (2018-2029)
Figure 23. North America Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2029)
Figure 24. U.S. Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Inactivated Influenza Vaccine Sales Market Share by Country (2018-2029)
Figure 27. Europe Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2029)
Figure 28. Germany Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Inactivated Influenza Vaccine Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2029)
Figure 35. China Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Taiwan Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Philippines Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Inactivated Influenza Vaccine Sales Market Share by Country (2018-2029)
Figure 46. Latin America Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. U.A.E Inactivated Influenza Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Inactivated Influenza Vaccine by Type (2018-2029)
Figure 56. Global Revenue Market Share of Inactivated Influenza Vaccine by Type (2018-2029)
Figure 57. Global Inactivated Influenza Vaccine Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Inactivated Influenza Vaccine by Application (2018-2029)
Figure 59. Global Revenue Market Share of Inactivated Influenza Vaccine by Application (2018-2029)
Figure 60. Global Inactivated Influenza Vaccine Price (US$/Unit) by Application (2018-2029)
Figure 61. Inactivated Influenza Vaccine Value Chain
Figure 62. Inactivated Influenza Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries